RMC No. 83-2022 updates the VAT-exempt medicines list under CREATE, covering diabetes, hypertension, mental illness, cancer, and kidney disease drugs.

Businesses that manufacture, import, distribute, sell, prescribe, dispense, procure, or account for medicines must immediately review their VAT treatment because RMC No. 83-2022 confirms updates to the List of VAT-Exempt Medicines under Republic Act No. 11534, or the CREATE Act. The update matters now for pharmacies, hospitals, clinics, drug wholesalers, pharmaceutical companies, corporate accountants, and finance teams because the VAT status of a medicine affects pricing, invoicing, accounting classification, tax reporting, and supporting documentation.

What RMC No. 83-2022 Changed

RMC No. 83-2022, issued on June 30, 2022, publishes the May 18, 2022 letter of the Food and Drug Administration of the Department of Health endorsing updates to the List of VAT-Exempt Medicines under the CREATE Act. The endorsement came from FDA OIC-Director General Dr. Oscar G. Gutierrez, Jr. and covers changes to medicines falling within specific disease categories recognized for VAT exemption purposes.

The core change is not a new general tax amnesty, registration rule, or filing form. It is an update to the official list that taxpayers must consult when determining whether particular medicines may be treated as VAT-exempt. In practical terms, taxpayers cannot rely only on a general description such as medicine, prescription drug, chronic disease treatment, hospital supply, or pharmaceutical product. The VAT treatment depends on whether the medicine is covered by the updated VAT-exempt medicines list endorsed by the FDA and published through the BIR issuance.

The update has three distinct effects. First, the List includes certain medicines prescribed for diabetes, hypertension, and mental illnesses. Second, the List deletes certain medicines for cancer and kidney diseases. Third, the List corrects the dosage form for a medicine for kidney diseases. Each of these changes can affect whether a product is treated as VAT-exempt at the point of sale, procurement, inventory classification, and tax reporting.

Who Is Most Affected

The most affected taxpayers are businesses in the pharmaceutical and healthcare supply chain. This includes drugstores, hospital pharmacies, pharmaceutical distributors, importers, wholesalers, manufacturers, healthcare institutions, clinics, and procurement units handling medicines for diabetes, hypertension, mental illness, cancer, and kidney diseases.

Corporate accountants and CFOs of healthcare companies should also treat this as a pricing and compliance issue, not merely a tax technicality. When a product is added to the VAT-exempt medicines list, systems may need to be updated so that invoices, official receipts, product masters, point-of-sale entries, and accounting reports reflect the correct VAT treatment. When a product is deleted from the VAT-exempt list, the opposite review becomes necessary: the business must determine whether the medicine should no longer be classified as VAT-exempt under the updated list.

In-house counsel and tax managers should pay particular attention to the deletion of certain medicines for cancer and kidney diseases. A product that was previously treated as VAT-exempt may require reclassification if it is among the deleted medicines. Likewise, the correction of the dosage form for a kidney disease medicine means that businesses should not rely on the name of the medicine alone; the dosage form can be material to the correct VAT classification.

Key Compliance Requirement and Effective Date

The key compliance requirement is to align VAT treatment with the updated List of VAT-Exempt Medicines under RMC No. 83-2022. The issuance date is June 30, 2022, while the FDA endorsement letter published by the circular is dated May 18, 2022. Businesses should therefore treat the update as a formal BIR-published reference for determining VAT exemption on the affected medicine categories.

The categories expressly identified in the issuance are medicines prescribed for diabetes, hypertension, mental illnesses, cancer, and kidney diseases. For diabetes, hypertension, and mental illnesses, the update includes certain medicines in the VAT-exempt list. For cancer and kidney diseases, the update deletes certain medicines. For kidney diseases, the update also corrects the dosage form for a medicine.

For tax and accounting teams, the immediate task is to compare the company’s medicine inventory, product catalog, procurement list, and sales database against the updated VAT-exempt medicines list. This review should focus on whether any product has been newly included, deleted, or affected by a dosage-form correction. The most important search phrases for taxpayers are RMC No. 83-2022 VAT-exempt medicines, CREATE Act VAT exemption medicines Philippines, FDA VAT-exempt medicine list, diabetes hypertension mental illness medicines VAT exempt, and cancer kidney disease medicines VAT deletion.

Penalties and Risks for Non-Compliance

RMC No. 83-2022 does not state a separate special penalty, surcharge, or fine for failure to follow the updated list. However, the absence of a special penalty in the issuance does not make the update optional. The practical compliance risk is that a business may apply the wrong VAT treatment to affected medicines, especially where products were added to or deleted from the VAT-exempt list, or where a kidney disease medicine has a corrected dosage form.

A mistaken VAT classification can create commercial and tax issues. If a business treats a medicine as VAT-exempt when it is no longer covered by the updated list, its billing, accounting, and tax reporting may become inconsistent with the BIR-published update. If a business fails to recognize a medicine that has been included in the VAT-exempt list, customers, institutional buyers, and auditors may question why the product was not treated in accordance with the updated VAT-exempt medicines list.

Practical Steps for Businesses

First, obtain the updated List of VAT-Exempt Medicines referenced in RMC No. 83-2022 and assign responsibility to tax, finance, pharmacy operations, procurement, and compliance teams. This should not be left only to front-line sales staff because the update affects product classification, invoicing, and internal controls.

Second, identify all medicines in the company’s records that relate to diabetes, hypertension, mental illnesses, cancer, and kidney diseases. These are the disease categories expressly mentioned in the issuance. The review should cover active inventory, historical product codes still used in billing systems, procurement templates, hospital formulary entries, and price lists.

Third, separate the products into three review groups: medicines newly included in the VAT-exempt list, medicines deleted from the list, and kidney disease medicines affected by a dosage-form correction. The dosage-form correction is especially important because the VAT treatment may depend not only on the active product name but on the specific form reflected in the official list.

Fourth, update accounting and billing systems so that the VAT classification in the system matches the updated list. For businesses with multiple branches or selling platforms, including physical stores, hospital pharmacies, and online ordering systems, the review should be coordinated across all channels to avoid inconsistent VAT treatment for the same medicine.

Fifth, keep documentation showing the basis for the VAT classification. Tax teams should maintain a compliance file identifying the relevant RMC number, the affected medicine category, the action taken by the company, and the date when the product master or billing treatment was updated. This creates an audit trail for internal review, external audit, and possible BIR inquiries.

Why This Matters for CFOs, Accountants, and Healthcare Businesses

RMC No. 83-2022 is important because VAT exemption for medicines is not determined by a business’s general understanding of healthcare policy. It depends on the official VAT-exempt medicines list as updated through the FDA endorsement and BIR publication. For companies dealing with diabetes, hypertension, mental illness, cancer, and kidney disease medicines, the issuance requires a concrete product-level review.

The most sensitive compliance point is the deletion of certain medicines for cancer and kidney diseases. Deletions are often harder to catch than new inclusions because older product setups may remain unchanged in accounting systems. The corrected dosage form for a kidney disease medicine also shows that technical product details matter. For a CFO or tax manager, the lesson is clear: do not rely only on disease category, brand familiarity, or historical billing treatment. Check the list, check the dosage form, and document the basis for the VAT treatment.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco assists businesses, healthcare institutions, pharmaceutical companies, distributors, and corporate finance teams with BIR compliance, VAT classification, tax risk review, and documentation of internal tax controls. For businesses affected by RMC No. 83-2022, our team can help review product classifications, identify VAT-exempt medicine issues, prepare compliance guidance for accounting and operations teams, and respond to tax questions arising from medicine sales and procurement.

For assistance with VAT-exempt medicines, BIR issuances, CREATE Act tax exemptions, and Philippine tax compliance, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.

Leave a Comment

Your email address will not be published. Required fields are marked *